Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Joerger

Showing results (11-20 of 141) with videos related to

Pageof 15
Sort By:
Tumori|November 27, 2018
Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancerMarco Siano, Vittoria Espeli, Markus Joerger
Journal of Geriatric Oncology|December 10, 2023
Geriatric evaluation methods in oncology and their use in clinical studies: A systematic literature reviewAmelie Stueger, Markus Joerger, Katelijne De Nys
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of developmentKira-Lee Koster, Jens Huober, Markus Joerger
Anticancer Research|June 1, 2018
Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck CancerMarco Siano, Nadine Jarisch, Markus Joerger, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 27, 2002
Gemcitabine-associated hemolytic-uremic syndromeRoland B Walter, Markus Joerger, Bernhard C Pestalozzi
British Journal of Clinical Pharmacology|November 28, 2020
Role of TDM-based dose adjustments for taxane anticancer drugsMarsilla Muth, Francis Williams Ojara, Charlotte Kloft, et al.
Onkologie|March 18, 2005
Von Hippel-Lindau disease--a rare disease important to recognizeMarkus Joerger, Dieter Koeberle, Hartmut P H Neumann, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 14, 2022
Current status and future outlooks on therapeutic drug monitoring of fluorouracilEduard Schmulenson, Nigina Zimmermann, Gerd Mikus, et al.
Frontiers in Oncology|November 23, 2020
Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid TumorsMariam Gachechiladze, Josef Skarda, Katerina Bouchalova, et al.
Therapeutic Drug Monitoring|March 17, 2015
Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of PaclitaxelStefanie Kraff, Andreas Lindauer, Markus Joerger, et al.
Pageof 15

Showing results (11-20 of 141) with videos related to

Sort By:
Pageof 15
Tumori|November 27, 2018
Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancerMarco Siano, Vittoria Espeli, Markus Joerger
Journal of Geriatric Oncology|December 10, 2023
Geriatric evaluation methods in oncology and their use in clinical studies: A systematic literature reviewAmelie Stueger, Markus Joerger, Katelijne De Nys
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of developmentKira-Lee Koster, Jens Huober, Markus Joerger
Anticancer Research|June 1, 2018
Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck CancerMarco Siano, Nadine Jarisch, Markus Joerger, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 27, 2002
Gemcitabine-associated hemolytic-uremic syndromeRoland B Walter, Markus Joerger, Bernhard C Pestalozzi
British Journal of Clinical Pharmacology|November 28, 2020
Role of TDM-based dose adjustments for taxane anticancer drugsMarsilla Muth, Francis Williams Ojara, Charlotte Kloft, et al.
Onkologie|March 18, 2005
Von Hippel-Lindau disease--a rare disease important to recognizeMarkus Joerger, Dieter Koeberle, Hartmut P H Neumann, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 14, 2022
Current status and future outlooks on therapeutic drug monitoring of fluorouracilEduard Schmulenson, Nigina Zimmermann, Gerd Mikus, et al.
Frontiers in Oncology|November 23, 2020
Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid TumorsMariam Gachechiladze, Josef Skarda, Katerina Bouchalova, et al.
Therapeutic Drug Monitoring|March 17, 2015
Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of PaclitaxelStefanie Kraff, Andreas Lindauer, Markus Joerger, et al.
Pageof 15